GRACELL BIOTECHNOLOGIES INC's ticker is GRCL and the CUSIP is 38406L103. A total of 33 filers reported holding GRACELL BIOTECHNOLOGIES INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,915 | -78.1% | 665 | -71.1% | 0.00% | – |
| Q2 2023 | $8,756 | -42.1% | 2,298 | -71.7% | 0.00% | – |
| Q1 2023 | $15,111 | +53.4% | 8,124 | +89.7% | 0.00% | – |
| Q4 2022 | $9,851 | -89.8% | 4,283 | -85.8% | 0.00% | – |
| Q3 2022 | $97,000 | -69.9% | 30,241 | -48.3% | 0.00% | – |
| Q2 2022 | $322,000 | +61.0% | 58,460 | -32.2% | 0.00% | – |
| Q1 2022 | $200,000 | -61.7% | 86,204 | -0.2% | 0.00% | – |
| Q4 2021 | $522,000 | +56.3% | 86,342 | +258.4% | 0.00% | – |
| Q3 2021 | $334,000 | – | 24,092 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 3,445,973 | $8,029,000 | 0.68% |
| Paradigm Biocapital Advisors LP | 783,445 | $1,825,000 | 0.48% |
| Orbimed Advisors | 7,884,870 | $18,372,000 | 0.30% |
| Vivo Capital, LLC | 961,359 | $2,240,000 | 0.15% |
| EcoR1 Capital, LLC | 1,559,710 | $3,634,000 | 0.11% |
| Temasek Holdings (Private) Ltd | 9,901,940 | $23,071,520 | 0.10% |
| Capital International, Inc./CA/ | 2,335,476 | $5,442,000 | 0.06% |
| Virtus ETF Advisers LLC | 24,728 | $58,000 | 0.03% |
| Capital International Sarl | 228,149 | $532,000 | 0.03% |
| FEDERATED HERMES, INC. | 1,298,578 | $3,026,000 | 0.01% |